Deng Caijiu, Huang Junming, Yu Qian, Han Jianjun, Jiang Yuanxue, Lin Liping, Cao Xiaolong
Department of Oncology, The Affiliated Panyu Central Hospital, Guangzhou Medical University, No. 8 Fuyu Road East, Panyu, Guangzhou, 511400, Guangdong, People's Republic of China.
Cancer Institute of Panyu District, The Affiliated Panyu Central Hospital, Guangzhou Medical University, Guangzhou, China.
Discov Oncol. 2025 Apr 10;16(1):503. doi: 10.1007/s12672-025-02271-2.
The efficacy of epidermal growth factor receptor EGFR tyrosine kinase inhibitors in cholangiocarcinoma (CCA) patients is still unknown. Here, we report a 67-year-old CCA patient with EGFR exon 19 deletion receiving afatinib treatment.
A 67-year-old male was referred to our hospital due to persistent abdominal pain for 3 months. Abdominal computed tomography showed a tumor with a diameter of 92 mm in the left liver with multiple intrahepatic metastases. Immunohistochemistry revealed that tumor cells were positive for CK7 and CK19, and negative for hepatocyte and CDX- 2. A pathological diagnosis of intrahepatic CCA was made. Since the patient declined standard chemotherapy, afatinib was administered as the first-line treatment. Upon disease progression, apatinib was introduced. Unfortunately, the patient ultimately succumbed to hepatic failure, with a total survival of 1.8 months.
In this report, the CCA patient with EGFR exon 19 deletion was unresponsive to afatinib treatment. However, genetic testing may be still worthwhile for CCA to increase the possible treatment options.
表皮生长因子受体（EGFR）酪氨酸激酶抑制剂在胆管癌（CCA）患者中的疗效尚不清楚。在此，我们报告一名67岁的EGFR外显子19缺失的CCA患者接受阿法替尼治疗的情况。
一名67岁男性因持续腹痛3个月转诊至我院。腹部计算机断层扫描显示左肝有一个直径92毫米的肿瘤，伴有多处肝内转移。免疫组织化学显示肿瘤细胞CK7和CK19呈阳性，肝细胞和CDX-2呈阴性。做出肝内CCA的病理诊断。由于患者拒绝标准化疗，阿法替尼作为一线治疗药物给药。疾病进展后，引入了阿帕替尼。不幸的是，患者最终死于肝功能衰竭，总生存期为1.8个月。
在本报告中，EGFR外显子19缺失的CCA患者对阿法替尼治疗无反应。然而，对于CCA患者，基因检测可能仍有价值，以增加可能的治疗选择。
